Reduced susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates is considered a risk factor for failure of glycopeptide therapy. We compared the prevalences of MRSA isolates with reduced glycopeptide susceptibility in patients with versus without persistent or recurrent MRSA bloodstream infections. A retrospective cohort study at the University Hospital of Geneva identified 27 patients with persistent or recurrent clonally related MRSA bacteremic episodes over an 8-year period, which included 208 consecutive nosocomial MRSA bacteremic episodes. Vancomycin and teicoplanin MICs were determined by a modified macrodilution assay allowing improved detection of glycopeptide-intermediate MRSA isolates (GISA), characterized by elevated teicoplanin or/and vancomycin MICs (≥ 4 μg/ml). For 16 patients (59%), their pretherapy and/or posttherapy MRSA isolates showed elevated teicoplanin MICs, among which 10 (37%) concomitantly displayed elevated vancomycin MICs. In contrast, 11 other patients (41%) were persistently or recurrently infected with non-GISA isolates. In comparison, only 39 (22%) of 181 single isolates from patients with no microbiological evidence of persistent or recurrent infections showed elevated teicoplanin MICs, among which 14 (8%) concomitantly displayed elevated vancomycin MICs. Clinical, microbiological, and pharmacokinetic variables for patients persistently or recurrently infected with GISA or non-GISA isolates were similar. Bacteremic patients with a poor response to glycopeptide therapy had a 2.8-fold- and 4.8-fold-higher rates of MRSA isolates displaying elevated teicoplanin and vancomycin MICs, respectively, than patients with single isolates (P < 0.0001). Detection of elevated teicoplanin MICs may help to predict a poor response to glycopeptide therapy in MRSA bacteremic patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3294919 | PMC |
| http://dx.doi.org/10.1128/AAC.05808-11 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antimicrobial Susceptibility of Various MRSA Clinical Isolates and the Impact of Glycopeptide MICs on Clinical and Microbiological Outcomes.
Infect Dis Clin Microbiol
June 2024
Department of Infectious Disease and Clinical Microbiology, Ankara University School of Medicine, Ankara, Türkiye.
Article Synopsis
- * Researchers compared clinical outcomes of patients with MRSA isolates that had high glycopeptide MICs (>1 mg/L) to those with low MICs (≤1 mg/L), identifying key risk factors like male sex, multiple comorbidities, and previous MRSA infections.
- * The findings suggest that a teicoplanin MIC value of >0.75 mg/L indicates a higher likelihood of treatment and microbiological failures, emphasizing the need to identify high-risk patients for better management of MRSA infections.
Lessons from Multiple Infections Such as Lymphoma Complicated with Pneumocystis Infection: A Case Report.
Infect Drug Resist
April 2024
Department of Pharmacy, Hangzhou Red Cross Hospital, Hangzhou, Zhejiang Province, People's Republic of China.
Background: Lymphoma is complicated by intricate infections, notably pneumonia (PJP), marked by rapid progression, respiratory failure, and high mortality. Rapid diagnosis of PJP and effective administration of the first-line treatment trimethoprim-sulfamethoxazole (TMP-SMX) are important. For patients intolerant to TMP-SMX, selecting appropriate alternatives is challenging, necessitating careful decisions to optimize diagnosis and treatment.
View Article and Find Full Text PDFBeyond One-Size-Fits-All: Tailoring Teicoplanin Regimens for Normal Renal Function Patients Using Population Pharmacokinetics and Monte Carlo Simulation.
Pharmaceutics
April 2024
Department of Clinical Pharmacology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14066, Republic of Korea.
In patients with normal renal function, significant teicoplanin dose adjustments are often necessary. This study aimed to develop a population pharmacokinetic (PK) model for teicoplanin in healthy adults and use it to recommend optimal dosage regimens for patients with normal renal function. PK samples were obtained from 12 subjects and analyzed using a population approach.
View Article and Find Full Text PDFAssociation of the predicted free blood concentration of teicoplanin with the development of renal dysfunction.
Eur J Clin Pharmacol
April 2024
Department of Clinical Laboratory Medicine, Shizuoka General Hospital, 4-27-1 Kita Ando Aoi-Ku, Shizuoka, 420-8527, Japan.
Article Synopsis
- The study investigates the link between teicoplanin (TEIC) blood concentration and renal dysfunction, noting that TEIC typically has a trough concentration of 15-40 µg/mL with a high protein binding rate of around 90%.
- Researchers found that 18% of patients experienced renal dysfunction, and those with higher predicted free trough concentrations (>4.0 µg/mL) had a significantly increased risk, with an odds ratio of 4.5.
- The findings suggest that managing free blood concentration levels of TEIC could help prevent renal dysfunction in patients.
Rapid and Effective Treatment of Peritonitis in Peritoneal Dialysis Patients with Intravenous Dalbavancin.
Am J Case Rep
January 2024
Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.
BACKGROUND Peritonitis is a complication associated with peritoneal dialysis (PD), which carries a significant morbidity and mortality risk. Empiric therapy must include coverage of gram-positive organisms; vancomycin is a recommended treatment option, particularly when MRSA infection is a risk. Vancomycin is cumbersome for patients, requiring therapeutic drug monitoring and re-administration by a healthcare provider.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!